|
Name |
Tetradecyl ether
|
Molecular Formula | C28H58O | |
IUPAC Name* |
1-tetradecoxytetradecane
|
|
SMILES |
CCCCCCCCCCCCCCOCCCCCCCCCCCCCC
|
|
InChI |
InChI=1S/C28H58O/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h3-28H2,1-2H3
|
|
InChIKey |
HANWHVWXFQSQGJ-UHFFFAOYSA-N
|
|
Synonyms |
Tetradecyl ether; 5412-98-6; Dimyristyl Ether; Ditetradecyl ether; n-tetradecyl ether; Myristyl Ether; 1-tetradecoxytetradecane; 1-(tetradecyloxy)tetradecane; Tetradecane, 1,1'-oxybis-; Y1W1K092JA; NSC-6360; NSC-78491; tetradecylether; UNII-Y1W1K092JA; EINECS 226-499-7; Tetradecylether; 97%; COSMACOL ETHER 14; SCHEMBL43244; BIS(TETRADECYL) ETHER; DIMYRISTYL ETHER [INCI]; DTXSID40202465; NSC6360; NSC 6360; NSC78491; MFCD00026607; NSC 78491; ZINC60164470; AKOS024429024; TETRADECANE, 1-(TETRADECYLOXY)-; T0091; D92301; Q27294155
|
|
CAS | 5412-98-6 | |
PubChem CID | 79433 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 410.8 | ALogp: | 13.4 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 26 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 9.2 | Aromatic Rings: | 0 |
Heavy Atoms: | 29 | QED Weighted: | 0.106 |
Caco-2 Permeability: | -5.221 | MDCK Permeability: | 0.00000549 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.059 |
30% Bioavailability (F30%): | 0.999 |
Blood-Brain-Barrier Penetration (BBB): | 0.003 | Plasma Protein Binding (PPB): | 99.25% |
Volume Distribution (VD): | 3.845 | Fu: | 1.08% |
CYP1A2-inhibitor: | 0.045 | CYP1A2-substrate: | 0.142 |
CYP2C19-inhibitor: | 0.123 | CYP2C19-substrate: | 0.053 |
CYP2C9-inhibitor: | 0.027 | CYP2C9-substrate: | 0.906 |
CYP2D6-inhibitor: | 0.08 | CYP2D6-substrate: | 0.01 |
CYP3A4-inhibitor: | 0.156 | CYP3A4-substrate: | 0.013 |
Clearance (CL): | 5.143 | Half-life (T1/2): | 0.012 |
hERG Blockers: | 0.735 | Human Hepatotoxicity (H-HT): | 0.005 |
Drug-inuced Liver Injury (DILI): | 0.152 | AMES Toxicity: | 0.004 |
Rat Oral Acute Toxicity: | 0.012 | Maximum Recommended Daily Dose: | 0.015 |
Skin Sensitization: | 0.977 | Carcinogencity: | 0.019 |
Eye Corrosion: | 0.991 | Eye Irritation: | 0.913 |
Respiratory Toxicity: | 0.353 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000434 | 0.851 | D00AOJ | 0.689 | ||||
ENC000401 | 0.843 | D00FGR | 0.468 | ||||
ENC000433 | 0.837 | D00STJ | 0.432 | ||||
ENC000435 | 0.835 | D07ILQ | 0.422 | ||||
ENC000446 | 0.824 | D0Z5SM | 0.418 | ||||
ENC000436 | 0.809 | D05ZPL | 0.362 | ||||
ENC000442 | 0.788 | D05ATI | 0.361 | ||||
ENC000443 | 0.784 | D0Z1QC | 0.342 | ||||
ENC000437 | 0.760 | D0T9TJ | 0.336 | ||||
ENC000432 | 0.753 | D0O1PH | 0.325 |